Market Overview

QUANTM Irradiation System™ Earns CE Mark Approval


First-in-class, advanced technology enables production of high-value
radioisotopes on medical cyclotrons

ARTMS Products today announced it received CE marking approval for its
first-in-class, advanced technology QUANTM Irradiation System™ for
producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical
cyclotrons. Cyclotron facilities are constantly facing higher isotope
costs and poor supply availability. Now, with CE marking, ARTMS' QUANTM
Irradiation System™ will help ease these issues.

"CE marking is an important milestone for ARTMS," remarked Dr. Kaley
Wilson, CEO of ARTMS Products. "There is a huge opportunity in providing
a cost effective and secured supply of radioisotopes to hospitals and
research institutions. ARTMS provides a more economical, environmentally
safe and secured supply of important radioisotopes than reactor-based
sources. Now, with CE marking approval, ARTMS can be readily integrated
in a standardized fashion into existing and emerging facilities which
ultimately leads to improved patient access and care across Europe."

Giving Cyclotron Facilities More Control Over the Supply of Medical

Unlike traditional reactor and generator production methods, which are
growing increasingly more expensive and cannot consistently supply user
requirements, the ARTMS QUANTM Irradiation System™ combines both local
production control and a cost-effective, easy-to-use solid target system
for production of radioisotopes on medical cyclotrons. Medical
radioisotopes are used in the field of nuclear medicine on a daily basis
for both medical diagnostic imaging and therapy, particularly in the
fields of oncology, cardiology and neurology.

The ARTMS QUANTM Irradiation System™ is currently available for most OEM
cyclotron systems and has been installed and is operating in a number of

About ARTMS Products

Based in Vancouver, British Columbia, ARTMS Products Inc. is a leader in
the development of novel technologies and products which enable the
production of the world's most-used diagnostic imaging isotope,
technetium-99m (Tc-99m), using local, hospital-based medical cyclotrons.
ARTMS holds the exclusive global commercialization rights to
award-winning and proprietary Canadian inventions which address these
challenges, and which offer the prospect of revolutionizing the nuclear
medicine industry.

For more information on the QUANTM Irradiation System™ and ARTMS
Products, please follow us on Twitter @Quantm99 and LinkedIn
and visit

View Comments and Join the Discussion!